Recruiting
Phase 3

Bumetanide vs. Furosemide

Sponsor:

Stacy Johnson

Code:

NCT06941415

Conditions

Cirrhosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bumetanide

Furosemide

Study Details

Brief summary:

Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis.

Clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. In patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. Bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. In this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.

Conditions

Cirrhosis

Study ID

NCT06941415

Start date

Jun 3, 2026

Status verified date

Jun, 2026

Completion date

Mar 31, 2029

Anticipated

Primary completion date

Mar 1, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • History of liver cirrhosis
  • Clinician placed an order for bumetanide or furosemide in electronic health record within 24 hours of presentation to the hospital

Exclusion Criteria:

  • Allergy to bumetanide or furosemide
  • Contraindication to diuretic administration (e.g. active bleeding, clinical suspicion of hepatorenal syndrome, hypotension)
  • Incarcerated or in custody of law enforcement
  • Diuretic ordered for purpose other than volume overload (e.g. hyperkalemia, continuation of home medication without clinical signs of volume overload)
  • Inpatient admission not anticipated
  • Not admitted to an inpatient hospital bed following initial evaluation in the emergency department

Study Design

Enrollment

500 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Bumetanide

experimental: Furosemide

Interventions

Bumetanide

Standard of care treatment with bumetanide (intravenous or oral administration) per treating clinician's orders

Furosemide

Standard of care treatment with furosemide (intravenous or oral administration) per treating clinician's orders

Primary outcome measure

  • Percent change in weight [ Time Frame: 7 days ]

Central Contacts and Locations

Central contacts

Andrea T White, PhD

8015817818andrea.white@hsc.utah.edu

Locations

University of Utah Hospital

Recruiting

Salt Lake City, Utah, United States, 84132

Contacts

Andrea T White, PhD

801-581-7818andrea.white@hsc.utah.edu

Principal Investigator:

Stacy A Johnson, MD

More Information

Sponsor

Stacy Johnson

Last update posted

Jun 16, 2026

Last verified

Jun, 2026

Keywords

  • cirrhosis
  • volume overload
  • diuresis
  • furosemide
  • bumetanide

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Stacy Johnson on 2026-06-16.